Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

63 results about "Sense strand" patented technology

In genetics, a sense strand, or coding strand, is the segment within double-stranded DNA that runs from 5' to 3', and which is complementary to the antisense strand of DNA, or template strand, which runs from 3' to 5'. The sense strand is the strand of DNA that has the same sequence as the mRNA, which takes the antisense strand as its template during transcription, and eventually undergoes (typically, not always) translation into a protein. The antisense strand is thus responsible for the RNA that is later translated to protein, while the sense strand possesses a nearly identical makeup to that of the mRNA. Note that for each segment of dsDNA, there will possibly be two sets of sense and antisense, depending on which direction one reads (since sense and antisense is relative to perspective). It is ultimately the gene product, or mRNA, that dictates which strand of one segment of dsDNA we call sense or antisense. But keep in mind that sometimes, such as in prokaryotes, overlapping genes on opposite strands means the sense for one mRNA can be the antisense for another mRNA.

Carbocyclic nucleoside-containing sirna conjugate, and pharmaceutical composition and use thereof

PCT designated stageWO2026137531A1DiseaseNucleotide
The present invention belongs to the technical field of medicine and provides a carbocyclic nucleoside-containing siRNA conjugate, and a pharmaceutical composition and a use thereof. The sense strand and / or antisense strand of the siRNA conjugate comprises at least one carbocyclic nucleoside represented by structural formula (I) below. The sense strand comprises at least 16 consecutive nucleotides of the nucleotide sequence 5'-GUCAUCCACAAUGAGAGUACA-3', and the antisense strand comprises at least 18 consecutive nucleotides of the nucleotide sequence 5'-UGUACUCUCAUUGUGGAUGACGA-3'. The carbocyclic nucleoside-containing siRNA conjugate provided by the present invention can be used for treating, preventing, and / or alleviating AGT-related diseases, such as hypertension.
Owner:REDFIELD PHARMACEUTICAL INC +1

RNAi molecules targeting the genome of the small cutworm

ActiveCN116334075BNucleotideGenetics
This invention discloses five RNAi molecules targeting the genome of the small cutworm, all of which are double-stranded RNA molecules composed of a sense strand and a complementary antisense strand, wherein the nucleotide sequence of the sense strand is selected from SEQ ID NOs:1-5. The lethality of these RNAi molecules against the small cutworm is all above 80%.
Owner:SHANGHAI PLANT SCI BIOTECHNOLOGY LTD

Sirna targeting AZGP1 and use thereof in preparation of drug for tumor treatment

PCT designated stageWO2026137674A1Pharmaceutical drugSense strand
Provided are an siRNA targeting AZGP1 and the use thereof in the preparation of a drug for tumor treatment. An siRNA molecule for inhibiting the expression of an AZGP1 gene may be AZGP1-1, AZGP1-2, AZGP1-3, AZGP1-4, AZGP1-5, AZGP1-6 or AZGP1-7. The siRNA molecule comprises a sense strand and an antisense strand. The sense strand can be at least partially reverse complementary to the antisense strand to form a double-stranded region. The provided siRNA molecule targeting the AZGP1 gene can inhibit the invasion, proliferation and epithelial-mesenchymal transition of breast cancer cells, and is of great significance for treating cancer, especially breast cancer, by inhibiting the expression of the AZGP1 gene.
Owner:TSINGHUA SHENZHEN INTERNATIONAL GRADUATE SCHOOL

SiRNA for inhibiting expression of NR1H3 gene and application thereof

The present application relates to siRNA for inhibiting NR1H3 gene expression and its modification and conjugate and application, belong to the field of biotechnology. The present application provides a kind of siRNA for inhibiting NR1H3 gene expression, its sense strand includes the first nucleotide sequence as shown in any one of SEQ ID NO.4, SEQ ID NO.15, SEQ ID NO.33 or SEQ ID NO.74-SEQ ID NO.80, its antisense strand includes the second nucleotide sequence as shown in any one of SEQ ID NO.40, SEQ ID NO.51, SEQ ID NO.70 or SEQ ID NO.81-87. Experiments have confirmed that the siRNA of the present application and its modification and conjugate are all higher inhibitory activity to NR1H3, therefore, in the preparation of drug for treating disease related to lipid metabolism has very application prospect.
Owner:BEIJING WINSUNNY PHARMA CO LTD

A trimethyl chitosan-hyaluronic acid-FMNL2 siRNA nanomedicine and its application

PendingCN122272529AEfficacyBiomarker (medicine)
This invention discloses a trimethyl chitosan-hyaluronic acid-FMNL2 siRNA nanomedicine and its applications. The siRNA molecule consists of a sense strand and an antisense strand, which are anti-complementary to form a double-stranded RNA structure. Each of the sense and antisense strands independently contains two pendant deoxythymidines at its 3' end. The nanomedicine uses trimethyl chitosan as its core framework, efficiently encapsulating the siRNA molecule through electrostatic interactions, and then modifying hyaluronic acid through electrostatic interactions to form core-shell structured nanoparticles. This invention forms a complete technology chain from target validation, siRNA sequence design, nanodelivery system construction, in vivo and in vitro efficacy verification to the development of combination drug strategies. It also provides quantifiable efficacy evaluation biomarkers, offering a clear basis for clinical patient screening and efficacy monitoring.
Owner:TONGJI HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI TECH

Microtubule-associated protein tau (MAPT) iRNA preparation composition and method of use thereof

This invention provides a double-stranded ribonucleic acid interference (dsRNAi) agent that targets the microtubule-associated protein tau (MAPT) gene. [Solution] A double-stranded ribonucleic acid (dsRNA) agent for inhibiting MAPT expression is provided, wherein the dsRNA agent comprises a sense strand and an antisense strand that form a double-stranded region, and the sense strand and antisense strand each contain a nucleotide sequence having a specific sequence and at least 15 consecutive nucleotides that differ by 3 or fewer nucleotides.
Owner:ALNYLAM PHARMACEUTICALS INC

Double‑stranded RNA composition for modulating DGAT2 expression, conjugate thereof, pharmaceutical composition comprising same, and use thereof

Provided are a double‑stranded RNA composition for modulating DGAT2 expression, a conjugate thereof, a pharmaceutical composition comprising same, and a use thereof. The double-stranded RNA comprises a sense strand and an antisense strand, and each nucleotide in the double-stranded RNA is independently a modified or unmodified nucleotide; the sense strand comprises one nucleotide sequence selected from the nucleotide sequences shown in SEQ ID NOs: 1-86 or a nucleotide sequence having no more than 3 nucleotide differences from the above sequences, and the antisense strand comprises one nucleotide sequence selected from the nucleotide sequences shown in SEQ ID NOs: 87-172 or a nucleotide sequence having no more than 5 nucleotide differences from the above sequences. The double-stranded RNA, the conjugate thereof and the pharmaceutical composition comprising same can be delivered to the liver by means of small nucleic acid delivery technology, and are expected to provide a safer and more effective therapeutic plan for patients with MASH-associated metabolic diseases.
Owner:SUZHOU SIRAN BIOTECHNOLOGY CO LTD

G protein-coupled receptor 75 (GPR75) iRNA composition and method of use thereof

This invention provides RNAi agents, such as dsRNA agents, that target the G protein-coupled receptor 75 (GPR75) gene. It also provides methods for using such RNAi agents to inhibit the expression of the GPR75 gene in a subject, and methods for treating or preventing GPR75-related diseases such as weight disorders, e.g., obesity. [Solution] A double-stranded ribonucleic acid (dsRNA) agent for inhibiting the expression of the GPR75 gene in cells is provided, comprising a sense strand and an antisense strand that form a double-stranded region, wherein the antisense strand comprises a region complementary to a portion of the mRNA encoding the GPR75 gene, each strand is independently 14 to 30 nucleotides long, and the sense strand or antisense strand is conjugated to one or more lipophilic portions.
Owner:ALNYLAM PHARMACEUTICALS INC +1

SiRNA targeting angiopoietin-like protein 3 gene and application thereof

PendingCN122278844ATG - TriglycerideDouble strand
This invention belongs to the field of biomedicine, specifically relating to siRNA targeting the angiopoietin-like protein 3 gene and its applications. The siRNA comprises a sense strand and an antisense strand, wherein the sense strand and the antisense strand are at least partially anticomplementary to form a double-stranded region. The sense strand or antisense strand consists of a 19-nucleotide blunt-ended complementary nucleotide sequence; or a sense strand of 19 nucleotides and an antisense strand of 21 nucleotides with overhanging ends. The siRNA of this invention can comprehensively lower blood lipids, and has good lipid-lowering effects on triglycerides and LDL-C, helping to significantly reduce the risk of atherosclerosis and cardiovascular disease.
Owner:YOUJIA (HANGZHOU) BIOMEDICAL TECH CO LTD

Double-stranded oligonucleotides targeting arg1 and conjugates, pharmaceutical compositions thereof and their use in pulmonary fibrosis

PendingCN122303236ANucleotideFibrosis
This application relates to the field of biotechnology, and particularly to Arg1-targeting double-stranded oligonucleotides and their conjugates, pharmaceutical compositions, and their application in pulmonary fibrosis. The Arg1-targeting double-stranded oligonucleotide comprises a sense strand and an antisense strand, wherein the sense strand and antisense strand are at least partially anticomplementary to form a double-stranded region; the nucleotide sequence of the sense strand comprises a sequence differing from the sequence shown in SEQ ID NO.1 by no more than 3 nucleotides, and the nucleotide sequence of the antisense strand comprises a sequence differing from the sequence shown in SEQ ID NO.2 by no more than 3 nucleotides. Using this Arg1-targeting double-stranded oligonucleotide and its conjugates, or pharmaceutical compositions containing it, to reprogram the nucleic acid of M2 macrophages in pulmonary fibrosis can effectively alter their pro-fibrotic functional state.
Owner:GUANGZHOU NAT LAB

New sirna, composition comprising same, and use

Provided is an siRNA that inhibits the expression of an RAGE gene, which siRNA comprises a sense strand and an antisense strand. The provided siRNA has good stability and can be used for efficiently and specifically inhibiting the expression of the RAGE gene, thereby providing important clinical value in the treatment of RAGE-related diseases.
Owner:CHANGCHUN GENESCIENCE PHARM CO LTD

SiRNA for inhibiting ar gene expression, conjugates thereof and use thereof

PendingCN122303233AImprove complianceLittle off-target toxicitySide effectNucleotide
This invention belongs to the field of biomedicine, specifically relating to siRNA that inhibits AR gene expression, comprising a sense strand and an antisense strand, wherein the sense strand and the antisense strand are at least partially anticomplementary to form a double-stranded region, and the sense strand or antisense strand consists of 19-25 nucleotides with blunt ends of complementary nucleotide sequences; or the antisense strand consists of 27 nucleotide sequences with overhangs. The siRNA of this invention can maintain long-term efficacy with a single dose, exhibiting good compliance in patients with chronic diseases such as androgenetic alopecia. Furthermore, it has lower off-target toxicity and fewer side effects compared to small molecule chemical drugs and hormone drugs.
Owner:YOUJIA (HANGZHOU) BIOMEDICAL TECH CO LTD

Small interfering RNA targeting TNF-alpha gene and use thereof

PendingCN122303224ANucleotideTherapeutic effect
This invention belongs to the field of biomedicine, specifically relating to small interfering RNA (sRNA) targeting the TNF-α gene; it includes a sense strand and an antisense strand; the sense strand and / or the antisense strand has a length ranging from 19 to 25 nucleotides, and the antisense strand is inversely complementary to a segment on the target gene. Furthermore, it achieves drug delivery of the small interfering RNA through a specific target gene, enabling precise drug targeting at the site of colonic inflammation, enhancing the therapeutic effect of IBD without causing systemic immunosuppression, thus providing a more precise and efficient gene regulation tool.
Owner:YOUJIA (HANGZHOU) BIOMEDICAL TECH CO LTD

SiRNA, conjugates and pharmaceutical compositions thereof for inhibiting expression of pcsk9 gene and uses thereof

PendingCN122445635ADiseasePharmacy medicine
The present application relates to siRNA, siRNA conjugates, pharmaceutical compositions comprising the same, and uses thereof for inhibiting the expression of PCSK9 gene. Each nucleotide in the siRNA is independently modified or unmodified, and the siRNA comprises a sense strand and an antisense strand. The siRNA, conjugates thereof, and pharmaceutical compositions thereof can be effective in treating and / or preventing diseases associated with overexpression of PCSK9 gene.
Owner:BEIJING WINSUNNY PHARMA CO LTD

Sirna targeting expression of activin a receptor type 1c (ACVR1c) gene, and conjugate thereof and use thereof

Provided in the present invention are an siRNA for inhibiting the expression of the activin A receptor type 1C (ACVR1C) gene, and a conjugate thereof. The siRNA comprises a sense strand and an antisense strand. The antisense strand comprises at least 17 consecutive nucleotides that differ from nucleotide sequences set forth in SEQ ID NO: 1236-SEQ ID NO: 2470 by no more than 4 nucleotides. The antisense strand is 17-30 nucleotides in length; and the sense strand is 17-30 nucleotides in length, and is at least partially or completely complementary to the antisense strand. The siRNA, siRNA conjugate and pharmaceutical composition provided in the present invention exhibit good stability, great ACVR1C gene inhibitory activity, and satisfactory cytotoxicity and immunostimulatory activity.
Owner:LEADERNA THERAPEUTICS LTD

Small interfering rnas inhibiting programmed cell death ligand 1 (PD-l1) and use thereof

PCT designated stageWO2026138438A1Death receptor ligandProgrammed cell death ligand 1
Small interfering RNAs inhibiting the programmed cell death ligand 1 (PD-L1) and the use thereof. Sense strands of the small interfering RNAs (siRNAs) have a length of 18-22 bases, and the siRNAs specifically pair with a specific region of a target gene. The siRNAs have the following uses: (1) treating cancer which involves high PD-L1 expression; or (2) inhibiting the expression of PD-L1 protein.
Owner:LNCTAC CO LTD

Sirnas for simultaneously inhibiting expression of two target genes, drug and use thereof

PendingEP4768585A1Organic active ingredientsSpecial deliverySubtilisinDyslipidemia
The present invention relates to a dual-targeting siRNA agent comprising two distinct siRNAs targeting two different genes or their pharmaceutically acceptable salts, wherein the two distinct siRNAs or their salts are linked by a pharmaceutically acceptable ligand. The siRNA is a dsRNA composed of a sense strand and an antisense strand, and the two different genes are selected from a group consisting of angiotensinogen (AGT), proprotein convertase subtilisin / kexin type 9 (PCSK9), and human angiopoietin-like protein 3 (ANGPTL3). The present invention provides the application of the dual-targeting siRNA agent in the preparation of drugs for preventing or treating diseases associated with hypertension and / or dyslipidemia. The dual-targeting siRNA agent described in the present invention can effectively inhibit the expression of two target genes simultaneously in vivo, offering the advantages of strong non-antagonistic activity and high safety. The present invention also provides the siRNAs targeting corresponding genes for the aforementioned dual-targeting siRNA agent and their use for preventing or treating diseases associated with hypertension and / or dyslipidemia.
Owner:BEBETTER MED INC

Inhbe gene-targeted double-stranded oligonucleotide, conjugate, composition and use thereof

Provided are an INHBE gene-targeted double-stranded oligonucleotide, a conjugate, and a composition, which relate to the technical field of nucleic acid drugs. The double-stranded oligonucleotide comprises a sense strand and an antisense strand. The antisense strand is complementary or substantially complementary to the sense strand; the sense strand comprises a nucleotide sequence identical or substantially identical to at least 15 contiguous nucleotides in a sequence of SEQ ID NO: 309, and said substantially identical means that there is no more than three nucleotide differences between the sense strand and the at least 15 contiguous nucleotides in the sequence of SEQ ID NO: 309. The double-stranded oligonucleotide can effectively inhibit the INHBE gene and treat patients suffering from metabolic diseases or metabolic syndrome and related diseases such as diabetes, hypertension and cardiovascular diseases.
Owner:RIGERNA THERAPEUTICS (SUZHOU) CO LTD

siRNAs and their conjugates that inhibit MSTN gene expression and their applications

This invention provides an siRNA for inhibiting MSTN gene expression, its conjugates, and their applications. The siRNA comprises a sense strand and an antisense strand, wherein the sense strand comprises nucleotide sequence I, and the antisense strand comprises nucleotide sequence II; each nucleotide in nucleotide sequence I and nucleotide sequence II is a modified or unmodified nucleotide. The siRNA, its conjugates, and the pharmaceutical composition provided by this invention exhibit strong inhibitory activity against the MSTN gene, significantly reducing the expression level of MSTN mRNA, and have low drug toxicity.
Owner:BEIJING GLYEXO GENE TECH CO LTD

Application of siRNA targeting RNF24 in preparation of medicine for treating liver cancer

The application relates to the technical field of gene targeting regulation, and provides application of siRNA targeting RNF24 in preparation of a liver cancer treatment drug. The sense strand and the antisense strand of the siRNA targeting RNF24 have nucleotide sequences shown in SEQ ID NO. 1-SEQ ID NO. 10, the siRNA can treat liver cancer by inhibiting the expression of an RNF24 gene and reducing the synthesis of a protein coded by the RNF24 gene, and can reduce the proliferation and migration abilities of liver cancer cells. The application solves the problems that existing liver cancer molecular targeted treatment drugs are limited, sequence silencing efficiency and specificity are difficult to be considered in siRNA targeted treatment, stability is insufficient, and delivery efficiency is low.
Owner:南昌大学第一附属医院

SiRNA targeting nsp9 of porcine epidemic diarrhea virus and antiviral application thereof

ActiveCN121160694BNucleotideCytotoxicity
The application discloses a kind of siRNA and antiviral application of targeting swine epidemic diarrhea virus Nsp9, belong to the field of biotechnology.The application designs a kind of siRNA targeting PEDV Nsp9, the nucleotide sequence of the siRNA sense strand is as shown in SEQ ID NO.3, the nucleotide sequence of the siRNA antisense strand is as shown in SEQ ID NO.4.It is proved by cell transfection experiment and virus infection experiment that the siRNA prepared in the application can significantly reduce the replication infection of PEDV in cells, effectively inhibit the expression of virus, and play an antiviral role;And the siRNA has no cytotoxicity, and has extensive application prospect.
Owner:INST OF ANIMAL SCI & VETERINARY MEDICINE SHANDONG ACADEMY OF AGRI SCI

DsRNA molecule targeting vdire1 gene and application thereof in preventing and treating verticillium wilt

The application discloses a dsRNA molecule targeting VdIRE1 a gene and application thereof in prevention and treatment of verticillium wilt, and belongs to the technical field of biotechnology. VdIRE1 The application specifically discloses a dsRNA molecule which can target a Verticillium dahliae gene (coding the amino acid sequence shown in SEQ ID NO: 3) and inhibit expression of the gene, and a nucleotide sequence of a sense strand of the dsRNA molecule is selected from SEQ ID NO: 4 or SEQ ID NO: 5. Based on the molecule, the application further provides a recombinant carrier containing a coding sequence of the molecule, a recombinant microorganism, a transgenic disease-resistant plant and an RNAi pesticide preparation. The schemes can be realized by means of host-induced gene silencing, microorganism-mediated gene silencing or preparation treatment, and can effectively reduce virulence of a pathogenic bacterium, thereby providing a new technical approach for green prevention and control of verticillium wilt.
Owner:BEIJING ZHONGKE KESHIBO BIOTECHNOLOGY CO LTD

Double-stranded oligonucleotides targeting the app gene and uses thereof

PendingCN122278846AInhibit expressioneffective treatmentDiseaseSense strand
This disclosure pertains to the field of biomedicine, specifically relating to double-stranded oligonucleotides targeting the APP gene and their applications. Specifically, it provides double-stranded oligonucleotide agents or their salts, conjugates, or compositions for inhibiting amyloid precursor protein (APP) expression, wherein the double-stranded oligonucleotide agent comprises a sense strand and an antisense strand forming a double-stranded region; wherein the antisense strand sequence comprises at least 15 consecutive nucleotides of any of the sequences shown in SEQ ID NO:1-154 with a difference of no more than 3 nucleotides, and / or the sense strand sequence comprises at least 15 consecutive nucleotides of any of the sequences shown in SEQ ID NO:155-308 with a difference of no more than 3 nucleotides. The double-stranded oligonucleotide agent or its salt for inhibiting APP expression disclosed in this application can significantly inhibit APP expression and can be used for the prevention and / or treatment of diseases or conditions mediated by the APP gene and / or associated with protein amyloidosis.
Owner:BEIJING ALNA TECHNOLOGY CO LTD

SiRNA for inhibiting expression of mitf gene and use thereof

PendingCN122303235ANucleotideImmunogenicity
This invention belongs to the field of biomedicine, specifically relating to siRNA that inhibits MITF gene expression and its applications. The siRNA comprises a sense strand and an antisense strand, which are at least partially anticomplementary to form a double-stranded region. The sense strand or antisense strand consists of a 19-nucleotide blunt-ended complementary nucleotide sequence, or a 19-nucleotide sense strand and a 21-nucleotide antisense strand with overhanging ends. The siRNA of this invention, bound to C16, provides advantages for transdermal delivery, including high penetration, targeting, rapid uptake, and low immunogenicity. By interfering with MITF mRNA expression, melanin production can be reduced at its source.
Owner:YOUJIA (HANGZHOU) BIOMEDICAL TECH CO LTD

Small interfering nucleic acids targeting tgfβr2 and uses thereof

This application relates to the field of biotechnology, and particularly to small interfering nucleic acids (SMEAs) targeting TGFβR2 and their applications, and further to conjugates, compositions, pharmaceutical compositions, and methods for inhibiting TGFβR2 in subjects for non-diagnostic and therapeutic purposes. The SMEA comprises a sense strand and an antisense strand; the nucleotide sequences of the sense strand and the antisense strand include sequences differing by no more than 3 nucleotides as shown in SEQ ID NO. 1-70; and the sense strand and the antisense strand are at least partially anticomplementary to form a double-stranded region. This SMEA targeting TGFβR2 can effectively reduce the transcriptional level of TGFβR2.
Owner:PEKING UNIVERSITY CHENGDU ACADEMY FOR ADVANCED INTERDISCIPLINARY BIOTECHNOLOGIES

Nucleic acid molecule for inhibiting mRNA expression via rnai, and use thereof

PCT designated stageWO2026145678A1Sense strandDouble stranded
Provided are a double-stranded RNA (dsRNA) molecule for inhibiting the expression of a target gene via RNAi, and the use thereof, and specifically provided are a modification scheme for the sense strand and antisense strand of a dsRNA.
Owner:CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO LTD

siRNA targeting interleukin-24 gene and its use in treating sepsis

The application discloses siRNA targeting interleukin-24 genes and application thereof in treatment of sepsis, and belongs to the technical field of biological medicine. The nucleotide sequence of the siRNA comprises a sense strand shown in SEQ ID NO. 1 and an antisense strand shown in SEQ ID NO. 2; the 5' end of the sense strand is modified by cholesterol, and the 3' end of the antisense strand is modified by methoxy. It is found through animal experiments that the siRNA can effectively inhibit excessive inflammatory response in a sepsis model and significantly improve the survival rate, thereby providing a brand-new candidate drug and a precise target for treatment of sepsis.
Owner:SOUTHERN MEDICAL UNIV STOMATOLOGICAL HOSPITAL (GUANGDONG STOMATOLOGICAL HOSPITAL GUANGDONG DENTAL DISEASE PREVENTION & TREATMENT GUIDANCE CENT) +1

siRNA for inhibiting LPA gene expression, a composition containing the same, and uses thereof

PendingKR1020260113053ASense strandBiochemistry
The present invention relates to siRNA for inhibiting LPA gene expression, a composition containing the same, and the use thereof, wherein the siRNA comprises a sense strand and an antisense strand, the antisense strand comprises a sequence complementary to the LPA mRNA sequence, and the sequence of the antisense strand comprises the sequence of any one of the antisense strands in Table 1.
Owner:재코레이 파마슈티컬 테크놀로지 씨오 엘티디

Dsrna targeting alk7 and compositions and uses thereof

PendingCN122278849ANucleotidePancreatic hormone
This invention belongs to the interdisciplinary field of pharmaceutical formulation and gene therapy, and discloses a dsRNA targeting ALK7, its composition, and its applications. The ALK7-targeting dsRNA comprises a sense strand and an antisense strand. The antisense strand includes a complementary region to the ALK7 RNA transcript, and the complementary region contains at least 15 consecutive nucleotides differing from one of the antisense sequences listed in Tables 1-2 by 0, 1, 2, or 3 nucleotides. The nucleotide sequence of the sense strand is as shown in any one of SEQ ID NO. 6-277, and the nucleotide sequence of the antisense strand is as shown in any one of SEQ ID NO. 278-549. The dsRNA of this invention, through chemical modification, optimizes its ribose and phosphate ester structures to exhibit resistance to nuclease degradation and significantly reduces the negative charge carried by the molecule, enhancing its ability to permeate cell membranes. Furthermore, this invention can reduce fat accumulation at its source, improve insulin resistance, and reduce the risk of other metabolic diseases.
Owner:SHANGHAI SHUYIN XINKE INTELLIGENT TECH CO LTD

A mismatched siRNA, siRNA conjugate, pharmaceutical composition and uses thereof

The present disclosure provides a mismatched siRNA for inhibiting gene expression, an siRNA conjugate, a pharmaceutical composition and uses thereof, the siRNA comprising a sense strand and an antisense strand, wherein the length of the sense strand and the antisense strand is 17-21 contiguous nucleotides and 19-23 contiguous nucleotides respectively, the sense strand and the antisense strand comprise one or more of 2'-methoxy modified nucleotides, 2'-fluoro modified nucleotides, 5'-VP modified nucleotides and comprise one or more phosphorothioate groups between adjacent two nucleotides, and at least one nucleotide at a position greater than 15 from the 5' end to the 3' end direction of the antisense strand is mismatched to the target gene.
Owner:CHENGDU GUOHONG PHARMA